All In Biotech

Drug Trial Radar · NCT07524946

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

A 12-Week, Phase 4, Open-Label Study To Assess Safety, Pharmacokinetics, and Treatment Effect of CABTREO (Clindamycin Phosphate 1.2%, Adapalene 0.15%, and Benzoyl Peroxide 3.1%) Topical Gel In Pediatric Participants Ages 9 to 11 Years, 11 Month With Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
Collaborators
MedTrials Incorporated
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, pharmacokinetics, and treatment effect for topically applied CABTREO lotion in pediatric participants ages 9 to 11 years, 11 months with Acne Vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.Drug

    The study drug will be applied topically to the treatment areas at home, each the morning, for a period of 12 weeks, with the exception of study visit days (baseline \[Day 1\], and Days 14, 15 \[PK substudy only\], 28, 29 \[PK substudy only\], 56, and 84) where study drug will be applied by the participants after the study visit is completed at the study center. The study drug will be applied as a thin coating that is gently rubbed into the skin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: All AEs will be followed from onset of the adverse event through the end of Study Week 12 visit
  2. Change in Inflammatory LesionsTime frame: Baseline through Week 12
  3. Change in Non-inflammatory LesionsTime frame: Baseline through Week 12
  4. EGSS ResultsTime frame: Baseline through Week 12

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Dermatology Trial Associates

    Bryant, Arkansas · Recruiting

  • Northwest Arkansas Clinical Trials Center

    Rogers, Arkansas · Recruiting

  • Center for Dermatology Clinical Research

    Freemont, California · Recruiting

  • Ablon Skin Institute and Research Center

    Manhattan Beach, California · Recruiting

  • Ziaderm Research, LLC

    North Miami Beach, Florida · Recruiting

  • Clinical Research Trials of Florida, Inc

    Tampa, Florida · Recruiting

  • DS Research of Kentucky, LLC

    Louisville, Kentucky · Recruiting

  • Michigan Center for Skin Care Research

    Clinton Township, Michigan · Recruiting

  • JDR Dermatology Research

    Las Vegas, Nevada · Recruiting

  • DermResearchCenter of New York

    Stony Brook, New York · Recruiting

  • Vitality Clinical Trials, LLC

    Woodbury, New York · Recruiting

  • Flourish Research Acquisition, LLC

    Apex, North Carolina · Not yet recruiting

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma · Recruiting

  • Cyn3rgy Research Corporation

    Gresham, Oregon · Recruiting

  • Breakaway Research Group

    Spokane, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.